Shares of STAAR Surgical Company (NASDAQ:STAA – Get Free Report) have earned a consensus rating of “Hold” from the thirteen brokerages that are covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $29.00.
A number of research firms have recently commented on STAA. Zacks Research raised STAAR Surgical from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 19th. Weiss Ratings reissued a “sell (d+)” rating on shares of STAAR Surgical in a research note on Wednesday, November 11th. Stifel Nicolaus raised STAAR Surgical from a “hold” rating to a “buy” rating and increased their target price for the stock from $28.00 to $31.00 in a research note on Tuesday, September 29th. Wall Street Zen upgraded shares of STAAR Surgical from a “hold” rating to a “buy” rating in a report on Saturday, November 7th. Finally, Veritas Investment Research set a $31.00 price target on shares of STAAR Surgical in a research note on Tuesday, September 29th.
Institutional Investors Weigh In On STAAR Surgical
STAAR Surgical Stock Down 1.4%
Shares of STAA stock opened at $26.01 on Thursday. STAAR Surgical has a 12-month low of $15.59 and a 12-month high of $35.87. The firm has a fifty day moving average of $23.02 and a 200-day moving average of $23.85. The firm has a market capitalization of $1.31 billion, a price-to-earnings ratio of -2,601,000.00 and a beta of 1.22.
STAAR Surgical (NASDAQ:STAA – Get Free Report) last posted its earnings results on Wednesday, November 4th. The medical instruments supplier reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.06. STAAR Surgical had a return on equity of 8.43% and a net margin of 0.16%. The firm had revenue of $83.41 million for the quarter, compared to analyst estimates of $78.73 million. During the same period in the previous year, the company posted $0.08 earnings per share. The company’s revenue for the quarter was down 11.9% on a year-over-year basis. Research analysts expect that STAAR Surgical will post 0.43 earnings per share for the current year.
STAAR Surgical announced that its Board of Directors has initiated a stock buyback program on Thursday, September 24th that authorizes the company to repurchase $50 million in outstanding shares. This buyback authorization authorizes the medical instruments supplier to repurchase up to 5.2% of its shares through open market purchases. Share buyback programs are typically a sign that the company’s leadership believes its stock is undervalued.
STAAR Surgical Company Profile
STAAR Surgical is a medical device company focused on ophthalmic surgery and vision correction. The company develops, manufactures and markets implantable lenses and related products designed to reduce or eliminate dependence on glasses or contact lenses. Its principal product line is the EVO Visian Implantable Collamer Lens (ICL), a lens implanted inside the eye to correct myopia, with or without astigmatism. Unlike procedures that remove corneal tissue, ICL surgery preserves the eye’s natural lens and is designed to be removable.
Featured Stories
- Five stocks we like better than STAAR Surgical
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.
